Loading news...
20/20 Biolabs (NASDAQ: AIDX - Get Free Report) and Applied Dna Sciences (NASDAQ: BNBX - Get Free Report) are both small-cap services companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Insider and Institutional Ownership 22.2% of
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), announced today that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has been granted a European patent by the European Patent Office (EPO) related to European Patent Application No.: 21882234.4 (EP4232569A1) entitled "Compositions and Methods for RNA Synthesis." The European patent grant follows a U.S. patent grant in 2024 and covers the composition of LineaRx's chemically modified RNA polymerase (.
20/20 Biolabs (NASDAQ: AIDX - Get Free Report) and Applied Dna Sciences (NASDAQ: BNBX - Get Free Report) are both small-cap services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends. Institutional and Insider Ownership 22.2% of
20/20 Biolabs (NASDAQ: AIDX - Get Free Report) and Applied Dna Sciences (NASDAQ: BNBX - Get Free Report) are both small-cap services companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation. Earnings and Valuation This table compares
Applied Dna Sciences (NASDAQ: BNBX - Get Free Report) and 20/20 Biolabs (NASDAQ: AIDX - Get Free Report) are both small-cap services companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation. Earnings and Valuation This table compares
20/20 Biolabs (NASDAQ: AIDX - Get Free Report) and Applied Dna Sciences (NASDAQ: BNBX - Get Free Report) are both small-cap services companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings. Earnings and Valuation This table compares
Applied Dna Sciences (NASDAQ: BNBX - Get Free Report) and 20/20 Biolabs (NASDAQ: AIDX - Get Free Report) are both small-cap services companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, earnings, risk, valuation and dividends. Earnings and Valuation This table compares
Applied Dna Sciences (NASDAQ: BNBX - Get Free Report) and 20/20 Biolabs (NASDAQ: AIDX - Get Free Report) are both small-cap services companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership. Profitability This table compares Applied Dna
Applied Dna Sciences (NASDAQ: BNBX - Get Free Report) and 20/20 Biolabs (NASDAQ: AIDX - Get Free Report) are both small-cap services companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk. Valuation and Earnings This table compares
20/20 Biolabs (NASDAQ: AIDX - Get Free Report) and Applied Dna Sciences (NASDAQ: BNBX - Get Free Report) are both small-cap services companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership. Profitability This table compares 20/20 Biolabs
Applied Dna Sciences (NASDAQ: BNBX - Get Free Report) and 20/20 Biolabs (NASDAQ: AIDX - Get Free Report) are both small-cap services companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Valuation and Earnings This table compares
Applied Dna Sciences (NASDAQ: BNBX - Get Free Report) and 20/20 Biolabs (NASDAQ: AIDX - Get Free Report) are both small-cap services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership. Analyst Ratings This is a summary
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company") today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has received two new orders for LineaDNA from well-established developers of genetic medicines. Production and shipment of both orders is expected to be completed prior to June 2026. "We're pleased to receive these new orders from leading genetic medicine companies,” said Clay Shorrock, President and CEO of BNBX. “We believe our con.
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), today announced the appointment of James Haft as an Independent Director and member of the Board's Nominating Committee, effective as of February 2, 2026. Mr. Haft is a recognized pioneer in digital asset investments and decentralized finance, bringing more than 35 years of experience spanning blockchain infrastructure, emerging markets, and traditional finance. Mr. Haft has served as a managing director at Bear.
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), today announced that Chief Investment Officer Patrick Horsman, CFA and Chairman of the Board Joshua Kruger will present live at the Digital Asset Virtual Investor Conference hosted by Virtual InvestorConferences.com, on January 27th, 2026 at 1:00PM EST. DATE: January 27th, 2026 TIME: 1:00PM EST Register here Mr.
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), today announced that Chief Investment Officer Patrick Horsman, CFA and Chairman of the Board Joshua Kruger will present live at the Digital Asset Virtual Investor Conference hosted by Virtual InvestorConferences.com, on January 27th, 2026 at 1:00PM EST. DATE: January 27th, 2026 TIME: 1:00PM EST Register here Mr. Horsman and Mr. Kruger will be available for 1x1 meetings on January 27-29. Participants may schedule.
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) (“BNBX” or the “Company”), today announced that it has received a $1.2M USD order for LineaDNA, representing the largest LineaDNA order in Company history. The order is an acceleration of an existing customer's annual purchasing cadence, consolidating what was originally planned as a two-year order cycle into an accelerated delivery schedule expected to be completed by May 2026. The order was placed by a global manufacturer of in vitro di.
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) (“BNBX” or the “Company”), today announced that it has successfully manufactured and shipped the largest single LineaDNA order in Company history, valued at over $390,000 USD. The approximately 5-gram shipment, manufactured by the Company's LineaRx, Inc. subsidiary, was delivered under the Company's previously announced supply agreement for the bulk manufacture of LineaDNA used as a functional component of a cancer diagnostic test (“the “.
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) (“BNBX” or the “Company”), today provided a corporate update highlighting its recent strategic treasury growth, expected significant narrowing of losses at its LineaRx, Inc. (“LineaRx”) subsidiary, and the launch of a new corporate website and branding. Significant Addition to BNB Treasury The Company has opportunistically deployed an additional approximately $3 million to acquire additional BNB tokens at an average price of approximately.
STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: BNBX) (the “Company”) today announced that it will change its name to BNB Plus Corp. (“BNB Plus”), reflecting the Company's commitment to delivering a yield-optimized, BNB-based digital asset treasury strategy leveraging the Binance ecosystem. Alongside the rebrand, the Company also announced the appointment of Josh Kruger as Chairman of the Board. Mr. Kruger has deep expertise in managing blockchain-native assets for yield.